Pharma Stocks
-
Cosette Pharmaceuticals Appoints David Bell as Chief Commercial Officer (Brands)
Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today it has appointed David Bell as Chief Commercial Officer…
Read More » -
Aurobindo Pharma Sees Sharp Open Interest Surge Signallin…
Open Interest and Volume Dynamics The latest data reveals that Aurobindo Pharma’s open interest (OI) in derivatives rose sharply by…
Read More » -
Gland Pharma Limited Just Recorded A 8.8% EPS Beat: Here’s What Analysts Are Forecasting Next
A week ago, Gland Pharma Limited (NSE:GLAND) came out with a strong set of full-year numbers that could potentially lead…
Read More » -
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower Today
What Happened? Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 2.8% in the morning session after Wells Fargo downgraded the…
Read More » -
Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance
Latitude Investment Management, an investment management firm, released its fourth-quarter 2025 investor letter. A copy of the letter can be…
Read More » -
Q1 2026 beat, raised outlook and steady dividend attract fresh attenti
GSK plc has surprised the market with better-than-expected Q1 2026 results, a guidance increase and a maintained dividend, putting the…
Read More » -
earnings momentum and US injectables footprint in fo
Generic drug maker Hikma Pharmaceuticals PLC has been drawing attention with recent earnings, a solid injectables pipeline and growing US…
Read More » -
Towa Pharmaceutical (TSE:4553) Valuation After Goodwill Impairment And FY2027 Recovery Outlook
Goodwill impairment hits guidance while dividend and FY2027 outlook steady Towa Pharmaceutical (TSE:4553) drew investor attention after announcing a large…
Read More » -
China trial update keeps pipeline in focus
AstraZeneca plc drew fresh investor attention after a May 11, 2026 trial update showed its real-world sinus surgery study in…
Read More » -
A Look At Lexicon Pharmaceuticals (LXRX) Valuation After Improved Q1 Revenue And Narrowed Net Loss
Lexicon Pharmaceuticals (LXRX) is back in focus after first quarter results showed revenue of US$21.1 million versus US$1.26 million a…
Read More »